Identification of DNA Methylation Biomarkers with Potential to Predict Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2021 Dec 19

PMID 34922619

Citations 14

Authors

Braydon Meyer

Samuel Clifton

Warwick Locke

Phuc-Loi Luu

Qian Du

Dilys Lam

Nicola J Armstrong

Beena Kumar

Niantao Deng

Kate Harvey

Alex Swarbrick

Vinod Ganju

Susan J Clark

Ruth Pidsley

Clare Stirzaker

Affiliations

Soon will be listed here.

Abstract

Neoadjuvant chemotherapy (NAC) is used to treat triple-negative breast cancer (TNBC) prior to resection. Biomarkers that accurately predict a patient's response to NAC are needed to individualise therapy and avoid chemotoxicity from unnecessary chemotherapy. We performed whole-genome DNA methylation profiling on diagnostic TNBC biopsy samples from the Sequential Evaluation of Tumours Undergoing Preoperative (SETUP) NAC study. We found 9 significantly differentially methylated regions (DMRs) at diagnosis which were associated with response to NAC. We show that 4 of these DMRs are associated with TNBC overall survival (P < 0.05). Our results highlight the potential of DNA methylation biomarkers for predicting NAC response in TNBC.

Citing Articles

Molecular profiling of breast cancer methylation pattern in triple negative versus non- triple negative breast cancer.

Mohanad M, Hamza H, Bahnassy A, Shaarawy S, Ahmed O, El-Mezayen H Sci Rep. 2025; 15(1):6894.

PMID: 40011499 PMC: 11865568. DOI: 10.1038/s41598-025-90150-9.

MethylBERT enables read-level DNA methylation pattern identification and tumour deconvolution using a Transformer-based model.

Jeong Y, Gerhauser C, Sauter G, Schlomm T, Rohr K, Lutsik P Nat Commun. 2025; 16(1):788.

PMID: 39824848 PMC: 11742067. DOI: 10.1038/s41467-025-55920-z.

Prognostic and Predictive Markers for Early Stage Triple-Negative Breast Cancer Treated With Platinum-Based Neoadjuvant Chemotherapy.

Zhao Z, Li L, He M, Li Y, Ma X, Zhao B Cancer Med. 2024; 13(20):e70336.

PMID: 39445528 PMC: 11499949. DOI: 10.1002/cam4.70336.

Improving efficacy of TNBC immunotherapy: based on analysis and subtyping of immune microenvironment.

Yang Y, Li H, Yang W, Shi Y Front Immunol. 2024; 15:1441667.

PMID: 39430759 PMC: 11487198. DOI: 10.3389/fimmu.2024.1441667.

Identification of autoantibodies as potential non-invasive biomarkers for intrahepatic cholangiocarcinoma.

Kajornsrichon W, Chaisaingmongkol J, Pomyen Y, Tit-Oon P, Wang X, Ruchirawat M Sci Rep. 2024; 14(1):20012.

PMID: 39198554 PMC: 11358490. DOI: 10.1038/s41598-024-70595-0.

References

Esserman L, Berry D, Cheang M, Yau C, Perou C, Carey L . Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2011; 132(3):1049-62. PMC: 3332388. DOI: 10.1007/s10549-011-1895-2. View

Pineda B, Diaz-Lagares A, Perez-Fidalgo J, Burgues O, Gonzalez-Barrallo I, Crujeiras A . A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Clin Epigenetics. 2019; 11(1):33. PMC: 6381754. DOI: 10.1186/s13148-019-0626-0. View

Blows F, Driver K, Schmidt M, Broeks A, van Leeuwen F, Wesseling J . Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010; 7(5):e1000279. PMC: 2876119. DOI: 10.1371/journal.pmed.1000279. View

Stirzaker C, Zotenko E, Song J, Qu W, Nair S, Locke W . Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nat Commun. 2015; 6:5899. DOI: 10.1038/ncomms6899. View

Liu P, Jiang W, Zhao J, Zhang H . Integrated analysis of genome‑wide gene expression and DNA methylation microarray of diffuse large B‑cell lymphoma with TET mutations. Mol Med Rep. 2017; 16(4):3777-3782. PMC: 5646955. DOI: 10.3892/mmr.2017.7058. View

Pidsley R, Zotenko E, Peters T, Lawrence M, Risbridger G, Molloy P . Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling. Genome Biol. 2016; 17(1):208. PMC: 5055731. DOI: 10.1186/s13059-016-1066-1. View

Alamgeer M, Ganju V, Kumar B, Fox J, Hart S, White M . Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Res. 2014; 16(2):R44. PMC: 4053180. DOI: 10.1186/bcr3648. View

Brockwell N, Rautela J, Owen K, Gearing L, Deb S, Harvey K . Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. NPJ Precis Oncol. 2019; 3:21. PMC: 6715634. DOI: 10.1038/s41698-019-0093-2. View

Wu S, Roden D, Wang C, Holliday H, Harvey K, Cazet A . Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. EMBO J. 2020; 39(19):e104063. PMC: 7527929. DOI: 10.15252/embj.2019104063. View

10.

Liedtke C, Mazouni C, Hess K, Andre F, Tordai A, Mejia J . Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008; 26(8):1275-81. DOI: 10.1200/JCO.2007.14.4147. View